strong earn confid build
report revenu line beat earn strongli vs
estim strong margin perform quarter xt strength continu
strong new custom growthboth competit displac greenfield
compani comprehens platform approach medic manag
start show result long-term strateg deal launch ahead schedul
provid upsid number particularli excit
potenti compani medadher segment import
medadher product grow recent chang industri increas
target reiter outperform
adj revenu adj ep adj revenu vs
consensu estim guid adj ep vs
consensu estim guid book competit
convers rate ltm competit vs
ivx workflow releas ahead schedul ivx workflow
releas earli june ahead schedul quarter
believ sizeabl market opportun given interest
greenfield custom signific time sinc earlier product robotrx
releas expect product could provid upsid number
focu
announc believ medadher solut like come
focu tradit dispensari look defend posit build
compet offer medadher offer enabl pharmaci
custom packag drug on-demand facilit higher complianc prescript
chang estim increas adj ep slightli
previou estim keep full-year revenu estim
model continu adj oper margin expans
year small increas book guidanc increas confid
estim
increas target increas price target base
adj ep increas multipl
believ traction multipl product opportun
medadher segment expand valuat prior target base
adj ep
design manufactur
adher analyt solut
primarili us market
analyst certif import disclosur see disclosur
medic adher segment slowli gain traction us
ivx workflow launch see slow steadi ramp
continu gain strength segment especi
aesynt portfolio medic adher build
steam releas segment strength
like drive compani growth encourag
momentum xt launch believ nich vendor
comprehens set medic manag solut
continu take signific share marketplac
aesynt portfolio drive deal flow up-sel includ xt
intern deal flow former cfo rob seim shift focu
abroad new hospit open
hospit budget continu improv product med
ivx workflow launch ramp quickli
xt intro enabl better organ revenu growth
medic adher segment quickli gain traction us
ivx workflow launch face implement issu
xt intro bring wors organ revenu growth
medic adher segment fail gain traction us
increas target increas target base adj ep increas multipl
believ traction multipl product opportun medadher segment expand valuat
prior target base adj ep
key risk see renew competit primari competitor us coupl appar push outsid
us
adj revenu adj ep adj revenu vs consensu
estim guid adj ep vs consensu estim
guid book competit convers rate ltm
product revenu servic revenu miss product revenu rose y/i vs
estim servic revenu rose vs estim
gm om adj gm vs estim year ago adj
oper margin vs estim year ago product gp
estim
guid introduc see adj revenu vs estim
consensu expect adj ep vs estim consensu
guid mostli rais adj revenu guid re-affirmed y/i vs
prior estim consensu adj ep guid rais
y/i midpoint vs consensu estim tax reform benefit
tax rate assum book guid rais vs
estim consensu repres healthi growth
win beaumont mi sign eight facil xt central pharmaci perform center brigham
 women expand xt analyt cleveland clinic oh use surem
adher advanc pharmaceut consult apc sign make xt option
behavior facil king faisal saudi arabia expand xt carilion clinic use robot
ivx launch ahead-of-schedul product launch ahead schedul june
ga live first custom site enter addit non-cancel contract
see healthi build pipelin product revenu contribut seen
modest given time book backlog revenu convers
servic revenu
incom expens net
provis incom tax
compani report oppenheim estim
